The potential role of nintedanib in treating colorectal cancer

Area of Science:

• Oncology
• Pharmacology

Background:

• Angiogenesis drives tumor growth, progression, and metastasis in cancers like metastatic colorectal cancer (mCRC).
• Vascular endothelial growth factors (VEGF) and their receptors (VEGFR) are key mediators of tumor angiogenesis.
• Existing therapies for mCRC include anti-angiogenic inhibitors like bevacizumab, aflibercept, ramucirumab, and regorafenib.

Purpose of the Study:

• To review the current state-of-the-art of anti-angiogenic inhibitors in mCRC treatment.
• To discuss the specific role and potential of nintedanib in managing mCRC.
• To explore nintedanib's potential in overcoming resistance to anti-angiogenic therapies.

Main Methods:

• A structured literature search of bibliographic databases and major scientific meetings was conducted.
• The review focused on peer-reviewed research and expert opinion regarding anti-angiogenic inhibitors in mCRC.
• Nintedanib's mechanism of action as a triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) was examined.

Main Results:

• In first-line therapy, nintedanib plus chemotherapy demonstrated non-inferiority to bevacizumab-based regimens in a Phase II trial.
• Nintedanib showed improved outcomes in heavily pretreated mCRC patients.
• Nintedanib's triple inhibition may help overcome resistance to VEGF-directed therapies by targeting compensatory angiogenesis.

Conclusions:

• Nintedanib represents a novel therapeutic option for mCRC, offering a distinct mechanism of action.
• Its efficacy in both first-line and later-stage treatment warrants further investigation.
• Nintedanib holds potential for overcoming acquired resistance to anti-angiogenic agents in mCRC.